Marvel Comics announced a new comic book starring a superhero that lives with type 1 diabetes. The project is being developed ...

In that light, the GLP-1 rebound effect is not an obstacle but an opportunity to chart a new, holistic course in obesity care ...

Delivered as a once-daily 30 mg/mL IV bolus injection over 15 seconds, Xifyrm can be used alone or alongside non-NSAID ...

Regulatory action was based on data from the Phase III IMforte trial, which showed that Zepzelca plus Tecentriq significantly ...

Results from a first-in-human Phase Ia/Ib trial show that LY4170156 demonstrated a notably high overall response rate in ...

Ron Lanton, Partner, Lanton Law, discusses the constitutional and statutory challenges facing the President’s use of executive orders to implement international drug pricing models such as the Most ...

The Lung Cancer Research Foundation is expanding its research advocate groups. The group is made up of lung cancer patients ...

Phenomix Sciences published the results of a study conducted in partnership with the Mayo Clinic that tested the ...

Recent innovations across the multiple ADC components, such as enhanced antibody-targeting to the tumors, better linker ...

Co-founder and CEO of CUTISS, Daniela Marino, PhD, talks about her switch from academia to the biotech industry and her 16-year journey developing a first-in-class personalized tissue therapy.

Approval of Enflonsia was based on data from the Phase IIb/III CLEVER trial, which showed a 60.5% reduction in medically ...

Early Phase I results for JNJ-79635322 demonstrated an 86.1% overall response rate in heavily pretreated multiple myeloma ...